Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Equity Average (2022 - 2026)

Axsome Therapeutics' Equity Average history spans 5 years, with the latest figure at $71.4 million for Q1 2026.

  • On a quarterly basis, Equity Average rose 29.63% to $71.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $71.4 million, a 29.63% increase, with the full-year FY2025 number at $72.7 million, down 41.41% from a year prior.
  • Equity Average hit $71.4 million in Q1 2026 for Axsome Therapeutics, down from $81.0 million in the prior quarter.
  • Over the last five years, Equity Average for AXSM hit a ceiling of $274.2 million in Q3 2023 and a floor of $14.9 million in Q2 2022.
  • Historically, Equity Average has averaged $109.9 million across 5 years, with a median of $86.3 million in 2022.
  • Biggest five-year swings in Equity Average: skyrocketed 1206.54% in 2023 and later plummeted 67.44% in 2024.
  • Tracing AXSM's Equity Average over 5 years: stood at $133.5 million in 2022, then surged by 72.52% to $230.2 million in 2023, then plummeted by 67.44% to $75.0 million in 2024, then rose by 8.08% to $81.0 million in 2025, then decreased by 11.81% to $71.4 million in 2026.
  • Business Quant data shows Equity Average for AXSM at $71.4 million in Q1 2026, $81.0 million in Q4 2025, and $73.4 million in Q3 2025.